Innovative Therapies for Children with Cancer in Europe

  • Innovative Therapies
    for Children with Cancer in Europe
  • Contact us

Innovative Therapies for Children with Cancer

  • A Prospective, Multicentric Clinical Proof-of-Concept Study to Stratify Targeted Therapies Adapted to Molecular Profiling of Relapsed or Refractory Pediatric Tumors

  • European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors in children

  • Ibrutinib randomized safety and efficacy study in pediatric patients with mature B-cell NHL, including Burkitt lymphoma/Leukemia and Diffuse Large B-cell Lymphoma

  • A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric Patients with Select Relapsed or Refractory Malignancies

  • A phase IB/II open label study of the MEK-inhibitor selumetinib in combination with dexamethasone for paediatric and adolescent patients with ≥2nd relapsed precursor B or T ALL

  • Phase II trial of nivolumab for pediatric and adult relapsing/refractory ALK+ anaplastic large cell lymphoma, for evaluation of response in patients with PD or as consolidative immunotherapy in patients in CR after relapse

  • Multicentre, open label, single arm Phase II study of Pegylated recombinant human arginase (BCT-100) in children > 1 year and <18 years with solid tumours, CNS malignancies and leukemias that are recurrent or refractory to standard therapy

  • T2015-001 A phase I study of Inotuzumab Ozogamycin as a single agent and in combination with chemotherapy for pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukemia